Kiadis announces new data demonstrating FC21-NK cells were well tolerated and showed encouraging signs of antitumor and suspected antimicrobial activity in 13 patients with relapsed/refractory acute myeloid leukemia (R/R AML)

NEXT STORY
NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study
PREV STORY
Global Oncology/Cancer Drugs Market To Grow At CAGR of 7.6% During 2020 To 2028
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Roche to present new pivotal data at ASH 2021 from broad and comprehensive portfolio, challenging treatment standards for people with blood disorders

author_avatar
NASDAQ Market News

Mental Healthcare Is Women’s Healthcare: Alpha Expands Telemental Health Offering

author_avatar
NASDAQ Market News

Jounce Therapeutics Announces Major Strategic Collaboration with Celgene Corporation to Develop Next-generation Immuno-oncology Therapies for Patients with Cancer

Jounce to receive upfront payment of $225 million, a $36 million equity investment and ...

author_avatar
NASDAQ Market News